对拉迈等人的评论。卟啉症患者肝细胞癌的风险：一项系统评价。2022年，，2947。 （注：原文中两个逗号处信息缺失，翻译时保留原样）
Comment on Ramai et al. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. 2022, , 2947.
作者信息
Lissing Mattias, Vassiliou Daphne, Harper Pauline, Sardh Eliane, Wahlin Staffan
机构信息
Hepatology Division, Department of Upper GI Diseases, Karolinska University Hospital, 17164 Stockholm, Sweden.
Department of Medicine, Huddinge, Karolinska Institutet, 14186 Stockholm, Sweden.
出版信息
Cancers (Basel). 2023 Jan 28;15(3):795. doi: 10.3390/cancers15030795.
Abstract
We read with interest this review by Ramai et al. [...].
摘要
我们饶有兴趣地阅读了拉迈等人的这篇综述。[...]
相似文献
1
Comment on Ramai et al. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. 2022, , 2947.对拉迈等人的评论。卟啉症患者肝细胞癌的风险：一项系统评价。2022年，，2947。 （注：原文中两个逗号处信息缺失，翻译时保留原样）
Cancers (Basel). 2023 Jan 28;15(3):795. doi: 10.3390/cancers15030795.
2
Reply to Lissing et al. Comment on "Ramai et al. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. 2022, , 2947".对利辛等人的回复。对“拉迈等人。卟啉症患者肝细胞癌的风险：一项系统评价。2022年，，2947”的评论。
Cancers (Basel). 2023 Feb 13;15(4):1187. doi: 10.3390/cancers15041187.
3
Comment on Wu et al. Baveno VII Criteria Is an Accurate Risk Stratification Tool to Predict High-Risk Varices Requiring Intervention and Hepatic Events in Patients with Advanced Hepatocellular Carcinoma. 2023, , 2480.对吴等人的评论：《巴韦诺 VII 标准是预测晚期肝细胞癌患者需要干预的高危静脉曲张和肝脏事件的准确风险分层工具》。2023 年，，2480。
Cancers (Basel). 2024 Feb 4;16(3):661. doi: 10.3390/cancers16030661.
4
Comment on: Jilkova, Z.M.; et al. "Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges" 2019, , 1554.评论：Jilkova, Z.M.等人，“肝细胞癌领域中对PD-1/PD-L1检查点抑制反应的预测因素：现状与挑战”，2019年，第1554页。
Cancers (Basel). 2020 Sep 18;12(9):2670. doi: 10.3390/cancers12092670.
5
Comment on Russo et al. Does Tumor Volume Have a Prognostic Role in Oropharyngeal Squamous Cell Carcinoma? A Systematic Review and Meta-Analysis. 2022, , 2465.对 Russo 等人的评论。肿瘤体积在口咽鳞状细胞癌中是否具有预后作用？一项系统评价和荟萃分析。2022 年， ，2465。
Cancers (Basel). 2022 Sep 1;14(17):4283. doi: 10.3390/cancers14174283.
6
Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review.卟啉症患者肝细胞癌的风险：一项系统评价
Cancers (Basel). 2022 Jun 15;14(12):2947. doi: 10.3390/cancers14122947.
7
Acute hepatic porphyria and hepatocellular carcinoma.急性肝卟啉病与肝细胞癌
Br J Cancer. 1988 Jan;57(1):117-20. doi: 10.1038/bjc.1988.23.
8
Is Acupuncture an Ideal Adjunctive Treatment for Cancer-Related Fatigue? Comment on Choi et al. Acupuncture for Managing Cancer-Related Fatigue in Breast Cancer Patients: A Systematic Review and Meta-Analysis. 2022, , 4419.针灸是癌症相关疲劳的理想辅助治疗方法吗？对崔等人的评论。针灸治疗乳腺癌患者癌症相关疲劳：系统评价和荟萃分析。2022年，，4419。
Cancers (Basel). 2022 Dec 30;15(1):223. doi: 10.3390/cancers15010223.
9
Mapping the unmappable? Epidemiology of pancreatic adenocarcinoma of varying onset: In response to Ramai et al.: Early- and late-onset pancreatic adenocarcinoma: A population-based comparative study.绘制难以绘制之物？不同发病时间的胰腺腺癌流行病学：回应拉迈等人：早发性和晚发性胰腺腺癌：一项基于人群的比较研究
Pancreatology. 2021 Jun;21(4):837-838. doi: 10.1016/j.pan.2021.04.003. Epub 2021 Apr 9.
10
Hepatocellular carcinoma in variegate porphyria: a case report and literature review.杂色卟啉症中的肝细胞癌：一例报告及文献综述
Ann Clin Biochem. 2015 May;52(Pt 3):407-12. doi: 10.1177/0004563214557568. Epub 2014 Oct 9.
引用本文的文献
1
Reply to Lissing et al. Comment on "Ramai et al. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. 2022, , 2947".对利辛等人的回复。对“拉迈等人。卟啉症患者肝细胞癌的风险：一项系统评价。2022年，，2947”的评论。
Cancers (Basel). 2023 Feb 13;15(4):1187. doi: 10.3390/cancers15041187.
本文引用的文献
1
Reply to Lissing et al. Comment on "Ramai et al. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. 2022, , 2947".对利辛等人的回复。对“拉迈等人。卟啉症患者肝细胞癌的风险：一项系统评价。2022年，，2947”的评论。
Cancers (Basel). 2023 Feb 13;15(4):1187. doi: 10.3390/cancers15041187.
2
Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals.急性肝性血卟啉症患者原发性肝癌的风险：1244 例个体的匹配队列研究。
J Intern Med. 2022 Jun;291(6):824-836. doi: 10.1111/joim.13463. Epub 2022 Mar 2.
3
Liver Transplantation for Acute Intermittent Porphyria.肝移植治疗急性间歇性血卟啉病。
Liver Transpl. 2021 Apr;27(4):491-501. doi: 10.1002/lt.25959. Epub 2021 Jan 29.
4
Penetrance and predictive value of genetic screening in acute porphyria.遗传性筛查在急性卟啉症中的外显率和预测价值。
Mol Genet Metab. 2020 May;130(1):87-99. doi: 10.1016/j.ymgme.2020.02.003. Epub 2020 Feb 10.
5
Porphyria cutanea tarda increases risk of hepatocellular carcinoma and premature death: a nationwide cohort study.迟发性皮肤卟啉症会增加肝细胞癌和过早死亡的风险：一项全国性队列研究。
Orphanet J Rare Dis. 2019 Apr 3;14(1):77. doi: 10.1186/s13023-019-1051-3.
6
Hepatocellular carcinoma in acute hepatic porphyrias: A Damocles Sword.急性肝性血卟啉症中的肝细胞癌：一把达摩克利斯之剑。
Mol Genet Metab. 2019 Nov;128(3):236-241. doi: 10.1016/j.ymgme.2018.10.001. Epub 2018 Oct 9.
7
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.欧洲肝脏研究学会临床实践指南：肝细胞癌的管理
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.
8
Acute hepatic porphyria and cancer risk: a nationwide cohort study.急性肝性卟啉症与癌症风险：一项全国性队列研究。
J Intern Med. 2017 Sep;282(3):229-240. doi: 10.1111/joim.12646. Epub 2017 Jul 20.
9
Acute Intermittent Porphyria: Predicted Pathogenicity of HMBS Variants Indicates Extremely Low Penetrance of the Autosomal Dominant Disease.急性间歇性卟啉症：HMBS基因变异的预测致病性表明常染色体显性疾病的外显率极低。
Hum Mutat. 2016 Nov;37(11):1215-1222. doi: 10.1002/humu.23067. Epub 2016 Sep 5.
10
Occurrence of Malignant Tumours in the Acute Hepatic Porphyrias.急性肝卟啉病中恶性肿瘤的发生
JIMD Rep. 2015;22:17-22. doi: 10.1007/8904_2015_406. Epub 2015 Feb 22.
Zotero 插件